Clinical trials: Delayed Gastric Emptying
Diabetic Gastroparesis
A Scintigraphy Study in Adults With Diabetic Gastroparesis
This is a randomized, double-blind, placebo-controlled scintigraphy study to investigate the effect of oral CIN-102 on gastric emptying and antral contractility in adults with diabetic gastroparesis.
- Trial name
- NCT04208698
- Testing
- CIN-102 Dose 1, CIN-102 Dose 2
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- CinDome Pharma, Inc.
Dyspepsia
Carbon-13 (13C)-Spirulina Platensis Gastric Emptying Breath Test (GEBT)
The purpose of this study is to compare stomach emptying using 13C-Spirulina platensis breath test and scintigraphy in healthy subjects and subjects with dyspepsia.
- Trial name
- NCT01248221
- Testing
- [13C]-Spirulina platensis and 99mTc sulfur colloid
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Gastroparesis
Study to Assess the Efficacy of VLY-686 in Relieving Symptoms of Gastroparesis
This is a multicenter, randomized, double-blind, placebo-controlled study to be conducted in the United States. One hundred fifty (150) subjects diagnosed with gastroparesis, who satisfy the selection criteria for the study, will…
- Trial name
- NCT02970968
- Testing
- VLY-686 (Tradipitant)
- Where
- 38 sites in United States
- Volunteers
- 152 people
- Sponsor
- Vanda Pharmaceuticals
Semaglutide-Induced Gastric Motility, Gastroparesis
Body Surface Gastric Mapping in Patients on Semaglutide
Glucagon-like receptor-1 agonists (GLP-1 RAs), such as Semaglutide (Ozempic), are a class of drugs used for glycemic control in diabetes, and for weight loss and management in obesity.
- Trial name
- NCT06401746
- Testing
- Gastric Alimetry
- Where
- Australia
- Volunteers
- 9 people
- Sponsor
- University of Western Sydney
Gastroparesis
Placebo Controlled Trial of Botulinum Toxin for Gastroparesis
It is hypothesized that in some patients with gastroparesis increased pyloric tone may be a contributing feature. Botox relaxes the pylorus so that food can empty the stomach more rapidly.
- Trial name
- NCT00372970
- Testing
- Botulinum toxin A
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Temple University
Gastroparesis
Effect of Vibrant Capsule on Gastric Emptying and Antropyloroduodenal Motility in Healthy Volunteers
The Vibrant capsule is a novel vibrating device for the treatment of gastrointestinal disorders. The effect of different vibrations on the motor functions of the gastrointestinal tract are unclear.
- Trial name
- NCT02736799
- Testing
- Vibrant Capsule (1 vibration), Vibrant Capsule (3 vibration), Vibrant Capsule (5 vibration)
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Vibrant Ltd.
Gastroparesis
Transcutaneous Electroacupuncture for Gastrointestinal Motility Disorders
Gastrointestinal (GI) dysmotility is common in GI motility disorders, such as functional dyspepsia (FD) gastroparesis and chronic constipation.
- Trial name
- TEA (NCT04349891)
- Testing
- Transcutaneous Electroacupuncture
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Johns Hopkins University
Crohn Disease, Diabetic Gastroparesis
Rifaximin in Patients With Diabetic Gastroparesis
Researchers are trying to determine if subjects with diabetic gastroparesis and symptoms of bloating will have a greater improvement in bloating symptoms when treated with rifaximin.
- Trial name
- NCT04254549
- Testing
- Rifaximin
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Mayo Clinic
Gastroparesis
A Study to Assess the Effect of Repeat Doses of GSK962040 on the Pharmacokinetics of L-DOPA in Subjects With Parkinson's Disease Exhibiting Delayed Gastric Emptying
Gastric emptying is the end-result of a complex and carefully regulated series of events which follow the ingestion of a meal, each of which is dependent on the other and subject to neurohormonal control.
- Trial name
- NCT01602549
- Testing
- GSK962040 (25 mg tablet)
- Where
- 11 sites in Australia, Germany and 2 more
- Volunteers
- 58 people
- Sponsor
- GlaxoSmithKline
Diabetes, Gastroparesis With Diabetes Mellitus
PET Imaging to Delineate Macrophage Activation in Diabetic Gastroparesis
Macrophage-driven immune dysregulation has been shown to be involved in pathophysiology of diabetic gastroparesis. Currently, there are no non-invasive ways to study macrophage activation in humans.
- Trial name
- NCT04762719
- Testing
- PET/CT Scan with 11C-ER176, Core biopsy of gastric muscle
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Idiopathic Gastroparesis, Diabetic Gastroparesis
Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis
To investigate the safety and efficacy of tradipitant versus placebo in relieving nausea and other symptoms of gastroparesis.
- Conditions
- Idiopathic Gastroparesis, Diabetic Gastroparesis, Gastroparesis
- Trial name
- NCT04028492
- Testing
- Tradipitant, Open Label Tradipitant
- Where
- 36 sites in United States
- Volunteers
- 979 people
- Sponsor
- Vanda Pharmaceuticals
Diabetic Gastroparesis
Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Women With Diabetic Gastroparesis
The purpose of this study is provide confirmation of the safety and efficacy of Metoclopramide Nasal Spray compared to placebo in reducing the symptoms of diabetic gastroparesis in adult women.
- Trial name
- NCT02025725
- Testing
- Metoclopramide Nasal Spray
- Where
- 50 sites in United States
- Volunteers
- 205 people
- Sponsor
- Evoke Pharma
Gastroparesis
Safety, PK and Efficacy of PCS12852 on Gastric Emptying Rate in Patients With Moderate to Severe Gastroparesis
This is a randomized, double-blind, placebo-controlled study that will compare the effect of 2 different dosage regimens of PCS12852 on gastric emptying time to placebo in both idiopathic gastroparesis (IG) and diabetic…
- Trial name
- MOMENTUM (NCT05270460)
- Testing
- PCS12852
- Where
- 9 sites in United States
- Volunteers
- 25 people
- Sponsor
- Processa Pharmaceuticals
Gastroparesis
GEBT Telehealth Administration Usability Study
The purpose of this study is to establish the usability of a telehealth platform for the administration of GEBT.
- Trial name
- NCT04684992
- Testing
- GEBT Telehealth Administration Usability
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Cairn Diagnostics
Gastric Emptying
Does Adding Milk to Tea Delay Gastric Emptying?
Most pre-operative fasting regimes dictate that if there is any milk added to tea or coffee, the preoperative fasting time should be extended from 2 to 6 hours.
- Trial name
- GETEAM (NCT01809938)
- Testing
- Black tea, Tea with milk
- Where
- United Kingdom
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Gastric Stasis
Multi-Channel Gastric Electrical Stimulation for the Treatment of Gastroparesis
Investigate the safety and efficacy of multi-channel gastric electrical stimulation in the treatment of patients with severe diabetic gastroparesis refractory to standard therapy.
- Trial name
- NCT00595621
- Testing
- Enterra Multi-Channel Phased Gastric Pacemaker (MGP-1)
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Kansas Medical Center
Gastroparesis
A Study of CNSA-001 in Women With Diabetic Gastroparesis
This study evaluates CNSA-001 (sepiapterin) in the treatment of women with moderate to severe diabetic gastroparesis. Participants will be randomized in a ratio of 1:1 to receive CNSA-001 20 (milligrams) mg/kilogram (kg)/day or…
- Trial name
- NCT03712124
- Testing
- CNSA-001
- Where
- 6 sites in United States
- Volunteers
- 21 people
- Sponsor
- PTC Therapeutics
Gastroparesis
Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis
GSK962040 is a novel small molecule motilin agonist. The Phase I studies (MOT107043 and MOT109681) demonstrated that single doses of GSK962040 up to 150 mg and repeat dosing of up to 125 mg/day for 14 days were well tolerated…
- Trial name
- NCT01262898
- Testing
- GSK962040 (5 mg tablet), GSK962040 (25 mg tablet), GSK962040 (125 mg tablet)
- Where
- 22 sites in United States, Australia and 4 more
- Volunteers
- 79 people
- Sponsor
- GlaxoSmithKline
Gastroparesis
Diabetic Gastroparesis Study 05
This open-label study is to assess the safety of continued treatment with relamorelin for participants who previously completed the RLM-MD-03 [NCT03420781] or RLM-MD-04 [NCT03383146] study and to provide treatment for these…
- Trial name
- NCT03786380
- Testing
- Relamorelin 10 μg
- Where
- 486 sites in United States, Argentina and 28 more
- Volunteers
- 202 people
- Sponsor
- Allergan
Gastroparesis
Enterra Therapy Gastric Stimulation System
Enterra Therapy Gastric Simulation System (Enterra Therapy) is indicated for the treatment of patients with long term, uncontrolled (not helped by medication) nausea and vomiting from gastroparesis of diabetic or idiopathic…
- Trial name
- Enterra (NCT00556166)
- Testing
- Enterra Therapy Gastric Stimulator
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Columbia University